{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-152039","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2026-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.614535+00:00","generated_at":"2026-05-15T06:35:27.463900+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Revolution Medicines' daraxonrasib Phase 3 trial meets OS endpoint: 13.2 vs 6.7 months, HR 0.40","bullets":["Phase 3 RASolute 302 trial: median OS 13.2 mo vs 6.7 mo for chemo (HR 0.40, p<0.0001); PFS also statistically significant.","Daraxonrasib generally well tolerated with manageable safety profile; no new safety signals.","Trial results considered final from first interim analysis; company to submit to FDA and other global regulators.","Data to support future NDA via a Commissioner’s National Priority Voucher."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-152039","json":"https://secwatch.observer/filing/0001193125-26-152039.json","markdown":"https://secwatch.observer/filing/0001193125-26-152039.md","text":"https://secwatch.observer/filing/0001193125-26-152039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/0001193125-26-152039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526152039/d69348d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:35:27.463900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}